COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES

• US 20100267052A1
• Filed: 05/10/2010
• Published: 10/21/2010
• Est. Priority Date: 09/01/2006
• Status: Abandoned Application

• Current Assignee: American Type Culture Collection
• Original Assignee: American Type Culture Collection
• Inventors: Auge, Catherine R., Simms, John R., Ikonomi, Pranvera, Gelber, Cohava, Liu, Liping, Xie, Zhidong
• Application Number:
  US12/776,601
• Publication Number:
  US 20100267052A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Claims

1. A method of diagnosing type 2 Diabetes or a pre-diabetic condition in a subject comprising

(a) separating proteins in a biological sample from the test subject;

(b) contacting the biological sample with an antibody that is raised against SEQ ID NO;

1 and substantially specifically recognizes fragments having homology to SEQ ID NO;

1 in a human biological sample;

(c) detecting a lower and a higher molecular weight peptides between about 60-80 kDa from the biological sample;

(d) measuring the amount of the lower and higher molecular weight peptides;

wherein if the amount of the lower and higher molecular weight products in the biological sample from the test subject is similar to the reference value obtained from a reference non-diabetic/non-pre-diabetic sample, the test subject is not affected with diabetes or pre-diabetes; and

wherein if the amount of the lower and higher molecular weight products in the biological sample from the test subject is similar to the reference value obtained from a reference diabetic sample or wherein the intensity of the lower molecular weight product is increased compared to the reference value obtained from the non-diabetic/non-pre-diabetic sample, the test subject is affected with diabetes; and

wherein if the amount of the lower and higher molecular weight products in the biological sample from the test subject is similar to the reference value obtained from a from a reference pre-diabetic sample or wherein if the intensity of the higher molecular weight product is decreased compared to the reference value obtained from the non-diabetic/non-pre-diabetic sample, the test subject is affected with pre-diabetes.

2. The method of claim 1, further comprising a system or a computer readable medium for causing a computer system to perform an analysis and display a diagnosis of type 2 Diabetes or a pre-diabetic condition in the subject based on the measured amount of lower and higher molecular weight product.

3. The method of claim 1, wherein the subject is human.

4. The method of claim 1, wherein only the higher molecular weight product is measured and if the higher molecular weight product is decreased by at least about two fold compared to the reference value obtained from the non-diabetic/non-pre-diabetic sample, the test subject is affected with pre-diabetes.

5. The method of claim 1, wherein only the lower molecular weight product is measured and if the intensity of the lower molecular weight product is increased by at least about two fold compared to the reference value obtained from the non-diabetic/non-pre-diabetic sample, the test subject is affected with diabetes or pre-diabetes.

6. The method of claim 1, wherein the antibody is a polyclonal antibody.

7. The method of claim 6, wherein the antibody is a polyclonal rabbit anti SEQ ID NO:

1 antibody.

8. The method of claim 1, wherein the separation is performed electrophoretically.

9. The method of claim 1, wherein the detection is performed using an immunoassay.

10. The method of claim 9, wherein the immunoassay is a Western blot assay.

11. The method of claim 1, wherein the biological sample is serum.

12. An immunoassay comprising

(a) separating proteins in a biological sample such that proteins with molecular weight 60-80 kDa are separated;

(b) contacting a biological sample from a subject with a first isolated antibody against SEQ ID NO;

1;

(c) allowing the first isolated antibody to form a reaction product;

(d) adding to the reaction product a second antibody that recognizes the first antibody, wherein the second antibody is conjugated to a detectable group or label;

(e) producing a detectable signal from the second antibody in step (d);

wherein increase by at least about two fold in the amount of the lower molecular weight product of the test sample compared to the lower molecular weight product of the reference value, wherein the reference value is a non-diabetic and non-pre-diabetic sample, is indicative of the test subject being affected with type 2 Diabetes or a pre-diabetic condition, and wherein decrease by at least about two fold in the amount of the higher molecular weight product of the test sample compared to the higher molecular weight product of the reference value, wherein the reference value is a non-diabetic and non-pre-diabetic sample, is indicative of the test subject being affected with pre-diabetic condition.

13. The immunoassay of claim 12, wherein the first antibody in an immunoassay is conjugated on a solid support.

14. The immunoassay of claim 12, wherein the solid support in an immunoassay is a test strip, a latex bead, a microsphere, a well or a plate.

15. The immunoassay of claim 12, wherein the detectable group or label from the second antibody used in an immunoassay is from an enzyme label, a radioactive label, a fluorescent label or a chemiluminescent label.

16. The immunoassay of claim 12, wherein only amount of the higher molecular weight product is measured.

17. The immunoassay of claim 12, wherein only amount of the lower molecular weight product is measured.

18. The immunoassay of claim 12, further comprising a system or a computer readable medium for causing a computer to perform an analysis and display a diagnosis of type 2 Diabetes or a pre-diabetic condition in the subject based on the detectable signal determined in step (e).